ロード中...
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
BACKGROUND: Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused t...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8218452/ https://ncbi.nlm.nih.gov/pubmed/34154614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01095-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|